ArticleThe journal of allergy and clinical immunology. In practice2022
COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab.
Article in The journal of allergy and clinical immunology. In practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Dupilumab therapy in atopic dermatitis is safe during COVID-19 infection era: A systematic review and meta-analysis of 1611 patients.Dermatologic therapy · 2022Pooled it
- Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Emerging Paediatric Uses of Dupilumab Beyond Approvals.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Review
- Autoimmune Skin Diseases in the Era of COVID-19: Pathophysiological Insights and Clinical Implications.Microorganisms · 2025Review
- Severe Asthma and Active SARS-CoV-2 Infection: Insights into Biologics.Biomedicines · 2025Review
- Real-World Assessment of Dupilumab in Chinese Atopic Dermatitis Patients: Efficacy, Safety, and Impact of Comorbidities.Journal of asthma and allergy · 2025Article
- Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells.Nature communications · 2024Article
- Impact of COVID-19 pandemic on adults and children with atopic dermatitis and food allergy: Systematic review.The journal of allergy and clinical immunology. Global · 2024Article
- Efficacy and Safety of Dupilumab in Older Patients (Aged 80 Years and Above) with Atopic Dermatitis: A Prospective Study.Drugs & aging · 2023Article
- COVID-19-Associated Disease Course Is Shortened in Moderate-to-Severe Atopic Dermatitis Patients Receiving Dupilumab Treatment: A Retrospective Cross-Sectional Study.Journal of clinical medicine · 2023Article
- Coronavirus infection in an unvaccinated atopic dermatitis patient under ongoing dupilumab therapy: eczema flare-up, but moderate COVID-19 symptoms.Allergo journal international · 2023Article
- Reduced COVID-19 vaccine response in patient treated with dupilumab for IgG4-related disease.The journal of allergy and clinical immunology. Global · 2023Article
- Dupilumab Use Is Associated With Protection From Coronavirus Disease 2019 Mortality: A Retrospective Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- The Impact of Immune-Modulating Treatments for Dermatological Diseases on the Risk of Infection with SARS-CoV-2 and Outcomes Associated with COVID-19 Illness.Current dermatology reports · 2023Review
- Acute and long-term immune responses to SARS-CoV-2 infection in unvaccinated children and young adults with inborn errors of immunity.Frontiers in immunology · 2023Article
- Management of patients with allergic diseases in the era of COVID-19.Clinical and experimental pediatrics · 2022Article
- IL-4 receptor blockade is a global repressor of naïve B cell development and responses in a dupilumab-treated patient.Clinical immunology (Orlando, Fla.) · 2022Article
- Inflammation Causes Exacerbation of COVID-19: How about Skin Inflammation?International journal of molecular sciences · 2022Review
- Healthcare Resource Utilization and Direct Cost of Patients with Atopic Dermatitis in Dubai, United Arab Emirates: A Retrospective Cohort Study.Dermatology and therapy · 2022Article
- Comparing the Cytokine Storms of COVID-19 and Pandemic Influenza.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the SARS-CoV-2/COVID-19 pandemic, we need to understand the impact of immunomodulatory medications on COVID-19 symptom severity in patients with inflammatory diseases, including the type 2/Th2 polarized skin disease, atopic dermatitis (AD).
objectiveBecause it is believed that type 1/Th1 immunity controls viral infections and that there is a Th1/Th2 counter-regulation, we hypothesized that Th2 targeting with the IL-4Rα-antagonist, dupilumab, in patients with moderate-to-severe AD would rebalance the Th1/Th2 axis, potentially leading to attenuated COVID-19 symptoms.
methodsA total of 1237 patients with moderate-to-severe AD in the Icahn School of Medicine at Mount Sinai Department of Dermatology were enrolled in a registry. Patients were screened for COVID-19-related symptoms and assigned a severity score (asymptomatic [0]-fatal [5]). Scores were compared among 3 treatment groups: dupilumab (n = 632), other systemic treatments (n = 107), and limited/no treatment (n = 498). Demographic and comorbid covariates were adjusted by multivariate generalized logistic regression models.
resultsThe dupilumab-treated group showed reduced incidence and severity of COVID-19 symptoms versus other treatment groups. Dupilumab-treated patients were less likely to experience moderate-to-severe symptoms versus patients on other systemics (P = .01) and on limited/no treatment (P = .04), and less likely to experience any symptoms versus patients on other systemics (P = .01). This effect was seen in our entire cohort and in the subgroup of patients with verified COVID-19 or high-risk exposure.
conclusionsPatients on dupilumab experienced less severe COVID-19 manifestations and lesser symptoms compared with patients on other systemics and on limited/no treatment. These results suggest that Th2 modulation with dupilumab may have a protective effect on anti-viral immune response in patients with AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.